Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0275 AUD | +10.00% | -.--% | -.--% |
02-26 | Exopharm Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
2023 | Exopharm to Cut CEO Role Amid Cost Reductions | MT |
Performance
1 day | +10.00% | ||
1 year | -42.11% | ||
3 years | -98.57% | ||
5 years | -97.41% |
Volumes
marketsBasic data
Highs and lows
Indicators
Sector Comparison - Other Biotechnology & Medical Research
Name | Change | 5d. change | 1st Jan change | 1-year change | Capi. | |
---|---|---|---|---|---|---|
+10.00% | -.--% | -.--% | -42.11% | 3.15M | ||
+0.68% | +2.45% | +2.43% | +24.74% | 42.75B | ||
-1.02% | +3.08% | +47.70% | -5.60% | 41.61B | ||
+3.45% | +6.68% | +12.06% | -16.46% | 41.34B | ||
+4.02% | +6.25% | -8.83% | +14.38% | 26.59B | ||
-2.19% | +1.33% | +6.65% | +54.46% | 25.49B | ||
+2.97% | +1.27% | -22.87% | -26.86% | 18.12B | ||
+0.96% | +6.24% | +30.41% | +93.59% | 12.24B | ||
+1.10% | -0.43% | -2.05% | +21.80% | 11.76B | ||
+2.35% | +2.60% | +9.21% | +3.46% | 11B | ||
+1.29% | +3.63% | -15.66% | -17.86% | 10.07B | ||
+1.32% | +2.39% | -5.74% | -8.54% | 9.22B | ||
+0.12% | +3.57% | +24.92% | -15.11% | 6.65B | ||
+3.41% | +20.21% | +8.55% | -34.40% | 6.44B | ||
+2.59% | +0.59% | +27.77% | +53.65% | 6.13B | ||
-.--% | -.--% | - | - | 6.07B | ||
Average | +1.93% | +3.39% | +7.64% | +6.61% | ||
Weighted average by Cap. | +1.24% | +3.94% | +10.16% | +9.71% |
Historical data
Date | Opening | High | Low | End-of-day | Volume |
---|
Monthly variations
Annual change
2023 | -81.67% | ||
2022 | -88.46% | ||
2021 | -8.77% | ||
2020 | +119.23% | ||
2019 | -52.73% | ||
2018 | +5.77% |
- Stock Market
- Equities
- EX1 Stock
- Quotes Exopharm Limited